[1] KUO C F,GRAINGE M J,MALLEN C,et al.Rising burden of gout in the UK but continuing suboptimal management:a nationwide population study[J].Ann Rheum Dis,2015,74(4):661-667.
[2] ZHU Y Y,PANDYA B J,CHOI H K.Comorbidities of gout and hyperuricemia in the US general population:NHANES 2007-2008[J].Am J Med,2012,125(7):679-687.
[3] KUO C F,GRAINGE M J,SEE L C,et al.Epidemiology and management of gout in Taiwan:a nationwide population study[J].Arthritis Res Ther,2015,17(1):13-20.
[4] LIU R,HAN C,WU D,et al.Prevalence of hyperuricemia and gout in mainland China from 2000 to 2014:a systematic Review and Meta-Analysis[J].Biomed Res Int,2015,20(1):1-12.
[5] SMITH E,HOY D,CROSS M,et al.The global burden of gout:estimates from the Global Burden of Disease 2010 study[J].Ann Rheum Dis,2014,73(8):1470-1476.
[6] GROUP T W.The World Health Organization Quality of Life assessment[WHOQOL]:position paper from the World Health Organization[J].Soc Sci Med,1995,41(10):1403-1409.
[7] DIBONAVENTURA M,ANDREWS L M,YADAO A M,et al.The effect of gout on health-related quality of life,work productivity,resource use and clinical outcomes among patients with hypertension[J].Expert Rev Pharm Out,2012,12(6):821-829.
[8] HICKEY A,BARKER M,MCGEE H,et al.Measuring health-related quality of life in older patient populations:a review of current approaches[J].Pharmaco Economics,2005,23(10):971-993.
[9] CHANDRATRE P,RODDY E,CLARSON L,et al.Health-related quality of life in gout:a systematic review[J].Rheumatology,2013,52(11):2031-2040.
[10] KHANNA P P,PEREZ-RUIZ F,MARANIAN P,et al.Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life:short form-36 is responsive to change in chronic gout[J].Rheumatology,2011,50(4):740-745.
[11] SCIRE C A,MANARA M,CIMMINO M A,et al.Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions:results from the KING observational study of the Italian Society for Rheumatology[SIR] [J].Arthritis Res Ther,2013,159(5):1-10.
[12] LI L,WANG H M,SHEN Y.Chinese SF-36 Health Survey:translation,cultural adaptation,validation,and normalisation[J].J Epidemiol Community Health,2003,57(4):259-263.
[13] TAYLOR W J,COLVINE K,GREGORY K,et al.The Health Assessment Questionnaire Disability Index is a valid measure of physical function in gout[J].Clin Exp Rheum,2008,26(4):620-626.
[14] RODDY E,ZHANG W,DOHERTY M.I s gout associated with reduced quality of life? A case-control study[J].Rheumatology,2007,46(9):1441-1444.
[15] LEUNG K F,WONG W W,TAY M S M,et al.Development and validation of the interview version of the Hong Kong Chinese WHOQOL-BREF[J].Qual Life Res,2005,14(5):1413-1419.
[16] KHANNA D,AHMED M,YONTZ D,et al.The disutility of chronic gout[J].Qual Life Res,2008,17(12):815-822.
[17] HIRSCH J D,LEE S J,TERKELTAUB R,et al.Evaluation of an instrument assessing influence of gout on health-related quality of life[J].J Rheumatol,2008,35(5):2406-2414.
[18] HIRSCH J D,LEE S J,TERKELTAUB R,et al.Evaluation of an instrument assessing influence of Gout on health-related quality of life[J].J Rheumatol,2008,35(12):2406-2414.
[19] COLWELL H H,HUNT B J,PASTA D J,et al.Gout Assessment Questionnaire:initial results of reliability,validity and responsiveness[J].Int J Clin Pract,2006,60(10):1210-1217.
[20] SPAETGENS B,van der LINDEN S,BOONEN A.The Gout Assessment Questionnaire 2.0:cross-cultural translation into Dutch,aspects of validity and linking to the International Classification of Functioning,Disability and Health[J].Rheumatology,2014,53(4):678-685.
[21] TENG G G,CHONG K J,LIM A,et al.Validity and reliability of the gout Impact scale in a multi-ethnic Asian population[J].Ann Rheum Dis,2013,72(1):344-345.
[22] AATI O,TAYLOR W J,SIEGERT R J,et al.Development of a patient-reported outcome measure of tophus burden:the Tophus Impact Questionnaire[TIQ-20] [J].Ann Rheum Dis,2015,74(12):2144-2150.
[23] LEE S J,HIRSCH J D,TERKELTAUB R,et al.Perceptions of disease and health-related quality of life among patients with gout[J].Rheumatology,2009,48(5):582-586.
[24] PRIOR J A,MALLEN C D,CHANDRATRE P,et al.Gout characteristics associate with depression,but not anxiety,in primary care:Baseline findings from a prospective cohort study[J].Joint Bone Spine,2016,16(1):1-16.
[25] CHANGCHIEN T C,YEN Y C,LIN C L,et al.High risk of depressive disorders in patients with gout:a nationwide population-based cohort study[J].Medicine,2015,941(52):1-6.
[26] ORTIZ R,ULRICH H,ZARATE C A Jr,et al.Purinergic system dysfunction in mood disorders:a key target for developing improved therapeutics[J].Prog Neuropsychopharmacol Biol Psychiatry,2015,57(1):117-131.
[27] MACHADO-VIEIRA R,SOARES J C,LARA D R,et al.A double-blind,randomized,placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania[J].J Clin Psychiat,2008,69(8):1237-1245.
[28] PRIOR J A,OGOLLAH R,MULLER S,et al.Gout,anxiety,and depression in primary care:a matched retrospective cohort study[J].Scan J Rheum,2015,44(3):257-258.
[29] KHANNA P P,NUKI G,BARDIN T,et al.Tophi and frequent gout flares are associated with impairments to quality of life,productivity,and increased healthcare resource use:Results from a cross-sectional survey[J].Health Qual Life Outcomes,2012,10(1):117-128.
[30] WU E Q,FORSYTHE A,GUERIN A,et al.Comorbidity burden,healthcare resource utilization,and costs in chronic gout patients refractory to conventional urate-lowering therapy[J].Am J Ther,2012,19(6):157-166.
[31] DOHERTY M,JANSEN T L,NUKI G,et al.Gout:why is this curable disease so seldom cured[J].Ann Rheum Dis,2012,71(11):1765-1770.
[32] KHANNA D,FITZGERALD J D,KHANNA P P,et al.2012 American College of Rheumatology guidelines for management of gout.Part 1:systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia[J].Arthritis Care Res,2012,64(10):1431-1446.
[33] SIVERA F,ANDRES M,CARMONA L,et al.Multinational evidence-based recommendations for the diagnosis and management of gout:integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative[J].Ann Rheum Dis,2014,73(2):328-335.
[34] de VERA M A,MARCOTTE G,RAI S,et al.Medication adherence in gout:a systematic review[J].Arthritis Care Res,2014,66(10):1551-1559.
[35] LI Q H,DAI L,LI Z X,et al.Questionnaire survey evaluating disease-related knowledge for 149 primary gout patients and 184 doctors in South China[J].Clin Rheumatol,2013,32(11):1633-1640.
[36] 李朝霞,李谦华,莫颖倩.痛风患者饮食控制相关知识的问卷调查[J].中山大学学报,2015,36(2):306-312.
[37] 苏海丹,温梦玲,郑春风.护理干预对老年痛风患者生活质量的影响[J].国际护理学杂志,2008,27(8):820-822.
[38] McGOWAN B,BENNETT K,SILKE C,et al.Adherence and persistence to urate-lowering therapies in the Irish setting[J].Clin Rheumatol,2016,35(1):715-721.
[39] 魏涛.痛风患者饮食依从性的调查分析[J].中国医药科学,2012,2(5):133-134.
[40] 李辉.健康教育在社区痛风患者中的应用[J].社区医学杂志,2014,12(22):45-46.
[41] 方钞,刘兰芬.痛风的护理进展[J].中国实用护理杂志,2011,27(2):50.
[42] 宋美艳,徐素清.系统性心理护理对痛风所致抑郁症患者的疗效影响及研究[J].大家健康,2015,7(1):1-2.
[43] 单颖.Neuman理论护理干预对抑郁症患者抑郁症状与生存质量的影响[J].现代医学,2016,35(3):388-392.
[44] ASCH S M,MCGLYNN E A,HOGAN M M,et al.Comparison of quality of care for patients in the Veterans Health Administration and patients in a national sample[J].Ann Int Med,2004,141(12):938-945.
[45] ROBINSON P C,TAYLOR W J,DALBETH N.An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population[J].J Rheumatol,2015,42(9):1702-1707.
[46] 李朝霞,李谦华,戴冽.痛风饮食治疗的新证据和新观点[J].中华风湿病学杂志,2014,18(10):716-719. |
